Evidence map›Paper›PMID 37807730›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2023

[Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].

Yun Chong Liu, Zong Long Wu, Li Yuan Ge, Tan DU, Ya Qian Wu, Yi Meng Song, Cheng Liu, Lu Lin Ma

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yun Chong LiuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Zong Long WuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Li Yuan GeDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Tan DUDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Ya Qian WuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Yi Meng SongDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Cheng LiuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Lu Lin MaDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Peking University · CNPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the potential mechanism of resistance to axitinib in clear cell renal cell carcinoma (ccRCC), with a view to expanding the understanding of axitinib resistance, facilitating the design of more specific treatment options, and improving the treatment effectiveness and survival prognosis of patients.

methodsBy exploring the half maximum inhibitory concentration (IC

resultsCell lines 786-O-R and Caki-1-R resistant to axitinib were successfully constructed

conclusionccRCC cell lines reduce apoptosis through the

Indexed as

Carcinoma, Renal CellKidney NeoplasmsApoptosisAxitinibbcl-2-Associated X ProteinCell Line, TumorCell ProliferationHumansNuclear ProteinsAxitinibbcl-2-Associated X ProteinNuclear ProteinsApoptosisAxitinibClear cell renal cell carcinomaDrug resistanceNuclear protein 1

Identifiers

PMID37807730
PMCPMC10560895
OpenAlexW4387440983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.